Navigation Links
Chiltern Early Phase: Fully Integrated and Business Ready

LONDON, Aug. 27 /PRNewswire/ -- Following the successful acquisition of Drug Development Solutions ('DDS') in February, Chiltern, a leading contract research organization, announced today that it has fully integrated its two early Phase units into a single operation branded as Chiltern Early Phase.

Chiltern Early Phase is providing high quality early phase services for the pharmaceutical industry via its two well established units in Slough (just outside of London) and Dundee, Scotland. With a total of 72 high care beds, 42 of which are based at Ninewells Hospital in Dundee, Chiltern Early Phase can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in First Time in Man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies.

Glenn Kerkhof, Chiltern's Chief Executive Officer said, "When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert Early Phase service at reasonable cost."

Dr Brian Sanderson, Medical Director of Chiltern Early Phase commented, "I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs over 1,250 people located in 23 offices throughout Europe, the Americas and Asia. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200


CA 92011


Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022


Richard Baptista

Chiltern International Ltd.

171 Bath Road





Tel: 44 (0) 1753 512 000

Fax: 44 (0) 1753 511 116


SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Contract With Chiltern
2. Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
3. Nano-sized electronic circuit promises bright view of early universe
4. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
5. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
8. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
9. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
10. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
11. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
Post Your Comments:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):